Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GRTS

Gritstone bio (GRTS) Stock Price, News & Analysis

Gritstone bio logo

About Gritstone bio Stock (NASDAQ:GRTS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.03
$0.63
52-Week Range
N/A
Volume
61.02 million shs
Average Volume
7.01 million shs
Market Capitalization
$3.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.17
Consensus Rating
Moderate Buy

Company Overview

Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

GRTS Stock News Headlines

Gritstone Bio sets sale of assets through Bankruptcy Court
Gritstone Oncology Inc (GRTSQ)
“All the land that you see I will give to you and your offspring forever…”
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
Gritstone bio, Inc. (GRTSQ)
Firm Retention Summary: Gritstone bio
Gritstone Oncology Pursues Restructuring Through Chapter 11
Why Gritstone Bio (GRTS) Stock Is Down 64% Today
See More Headlines

GRTS Stock Analysis - Frequently Asked Questions

Gritstone bio, Inc. (NASDAQ:GRTS) issued its earnings results on Tuesday, August, 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.12. The company earned $0.92 million during the quarter, compared to analyst estimates of $2.77 million. Gritstone bio had a negative trailing twelve-month return on equity of 328.51% and a negative net margin of 910.50%.

Gritstone bio (GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gritstone bio investors own include Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), American Water Works (AWK) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/13/2024
Today
7/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRTS
CIK
1656634
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$0.50
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$138.49 million
Net Margins
-910.50%
Pretax Margin
-910.50%
Return on Equity
-328.51%
Return on Assets
-82.53%

Debt

Debt-to-Equity Ratio
1.83
Current Ratio
2.54
Quick Ratio
2.54

Sales & Book Value

Annual Sales
$496 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
108,569,000
Free Float
111,837,000
Market Cap
$3.50 million
Optionable
Optionable
Beta
0.49
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:GRTS) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners